
17 November 2026
("EDX Medical" or the "Group" or "the Company”)
CEO APPOINTMENT & BOARD CHANGES
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company has appointed Martin Walton as Chief Executive Officer.
Martin Walton, currently Deputy Chairman of the Company, succeeds with immediate effect Dr Michael Hudson who as co-founder will continue to support the company as a consultant and Director, International Strategy & Partnerships, but has stepped down from the EDX Medical board with effect from close of business on 16 November 2026.
Professor Sir Christopher Evans, OBE, founder and Chief Scientific Officer of EDX Medical, has been appointed Deputy Chairman.
Martin Walton has more than 35 years' experience in finance and investment, latterly as vice chair, Europe and Asia Pacific, of a major Canadian bank. He has spent 15 years as an investor or officer in global life sciences companies, including Verona Pharma, Kymab, Arix Bioscience and Simbec-Orion. He has completed multiple corporate transactions creating value in private and publicly listed companies as well as building and overseeing commercial operations.
Dr Mike Owen, chairman of EDX Medical, commented: “EDX Medical is delighted to announce Martin’s appointment as CEO. This reflects the growth phase the Company has reached, and Martin’s extensive sector experience is a great asset as we drive forward our commercial operations.
“We are extremely grateful to Mike Hudson for his contribution as CEO from the earliest days of EDX Medical and look forward to him fulfilling an extremely important international and partnerships’ role.”
Professor Sir Christopher Evans, founder of EDX Medical, commented: "The board of EDX Medical has been strengthened significantly recently with the addition of three highly experienced independent non-executive directors and Martin’s financial and commercial experience made him an obvious choice to build on Mike Hudson’s success and lead the executive team as we continue to expand our commercial operations.”
ENDS
Contacts:
|
EDX Medical Group plc |
|
|
Martin Walton, Chief Executive Officer |
+44 (0) 7917531288
martin@edxmedical.com |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.